2-chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma

2-chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma

Author Colleoni, Gisele Wally Braga Autor UNIFESP Google Scholar
Duarte, Luiz Cláudio de Carvalho Autor UNIFESP Google Scholar
Kerbauy, Fábio Rodrigues Autor UNIFESP Google Scholar
Veras, Marcos Serra de Lobão Autor UNIFESP Google Scholar
Yunis, Melissa Palis Autor UNIFESP Google Scholar
Alves, Antonio Correa Autor UNIFESP Google Scholar
Souza, Vanda Akiko Ueda Fick de Google Scholar
Bordin, Jose Orlando Autor UNIFESP Google Scholar
Oliveira, José Salvador Rodrigues de Autor UNIFESP Google Scholar
Institution Universidade de São Paulo (USP)
Universidade Federal de São Paulo (UNIFESP)
Abstract There is currently no consensus on the best treatment for unresectable hyaline-vascular variant or for multicentric Castleman's disease (MCD), because none of the reported regimens have consistently produced complete response or durable remission in the majority of patients. in the present study, we report on the use of 2-CdA (2-chloro-deoxyadenosine) in three patients, two of them with MCD and one with unresectable hyaline-vascular type disease. Relapse-free survival of the responding patients was 24 and 20 months. Later, both patients evolved to non-Hodgkin's lymphoma (NHL) (diffuse large B- cell lymphoma and peripheral T-cell NHL, respectively). 2-CdA typically causes a long-lasting state of immunodeficiency and the profound influence of this drug on the immune system has raised questions concerning the emergence of secondary neoplasms after its use. Therefore, it is reasonable to conclude that: 1) 2-CdA can induce durable complete remission in MCD patients but unfortunately it cannot cure the disease; 2) the possibility that 2-CdA may accelerate the transformation of MCD to NHL cannot be ruled out.
Language English
Date 2003-11-01
Published in Acta Oncologica. Oslo: Taylor & Francis As, v. 42, n. 7, p. 784-787, 2003.
ISSN 0284-186X (Sherpa/Romeo, impact factor)
Publisher Taylor & Francis As
Extent 784-787
Origin http://dx.doi.org/10.1080/02841860310003527
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000186273900016
URI http://repositorio.unifesp.br/handle/11600/27453

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account